Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Acetylcarnitine is an acetylated form of the amino acid derivative L-carnitine that assists in mitochondrial fatty acid metabolism. It is under investigation as a treatment for numerous conditions, including neuropathy, depression, and dementia. Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India.
- Mechanism
- Curator reviewed
The mechanisms of action of acetylcarnitine have not been fully elucidated, but it seems that the main role of acetylcarnitine is to donate an acetyl group during fatty acid metabolism to help transport fatty acids, such as acetyl CoA, into the mitochondrial matrix where fatty acid metabolism occurs. Additionally several studies have found that separate from its metabolic role, acetylcarnitine has neuromodulatory, neurotrophic, and neuroprotective effects that most likely are involved in its positive effects in neurological diseases. In its role in treating male infertility, acetylcarnitine increases the active movement of sperm cells. One study has also mentioned a role for acetylcarnitine as an antioxidant. The study found that through the receptor, tyrosine kinase A, acetylcarnitine was able to decrease the production of free radicals, peroxidation of lipids, and oxidation of proteins as well as decrease glutathione levels and increase thioredoxin.
- Primary indication
- Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation;...Curator reviewed · 3 structured indications
- Formula / weight
- C9H17NO4 · 203.238 g/mol (avg)
- Also known as
- acetyl-L-carnitine · O-Acetylcarnitine
Resolves to
RDHQFKQIGNGIED-MRVPVSSYSA-NSMILESCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)CWhat you can answer from here — as of July 09, 2026
Which drugs share a target with Acetylcarnitine, and which of those have an active Phase 3 trial?